SCHEMBL5143534

SCHEMBL5143534

COc1cc2c(cc1OC)NCC=C2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.36
CYP3A4 P08684 1/20 0.35
MAPT P10636 1/20 0.35
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
CA14 Q9ULX7 1/20 0.33
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 2/20 0.33
GLA P06280 2/20 0.33
MAOA P21397 2/20 0.33
GRIN2D O15399 1/20 0.31
GRIN3B O60391 1/20 0.31
GRIN1 Q05586 1/20 0.31
GRIN2A Q12879 1/20 0.31
GRIN2B Q13224 1/20 0.31
GRIN2C Q14957 1/20 0.31
GRIN3A Q8TCU5 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22641693 0.87 HTR2A (0.32) BRD4MAPTKDM4EKMT2A
SCHEMBL29993463 0.82 CHRNA7 (0.45)
SCHEMBL27744105 0.80 MAPT (0.38) BRD4CYP3A4MAPTCA12CA1
SCHEMBL4366398 0.78 PDE3B (0.41) MAPTCA12CA1CA2CA7
SCHEMBL9740835 0.72 TSHR (0.40) ALDH1A1KDM4EGAATSHRKMT2A
SCHEMBL13354838 0.67 LMNA (0.34) CA2MAOA
SCHEMBL4526375 0.67 CA1 (0.37) CYP3A4MAPTCA12CA1CA2
SCHEMBL15161193 0.67 GAA (0.38) MAPTALDH1A1GAA
SCHEMBL1438677 0.67 GAA (0.37) MAPTALDH1A1GAAKMT2A
SCHEMBL3903265 0.65 CYP3A4 (0.50) BRD4CYP3A4MAPTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9174947-B2 c-Met modulators and methods of use Exelixus, Inc. (US) 2015-11-03 US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET BRD4 835/4885CYP3A4 1264/4885MAPT 4161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.